|
gptkbp:instanceOf
|
gptkb:drug
recombinant hormone
|
|
gptkbp:administeredOncePer
|
week
|
|
gptkbp:approvalYear
|
2010
|
|
gptkbp:approvedBy
|
gptkb:European_Union
|
|
gptkbp:ATCCode
|
gptkb:G03GA09
|
|
gptkbp:brand
|
gptkb:Elonva
|
|
gptkbp:CASNumber
|
82752-99-6
|
|
gptkbp:contraindication
|
pregnancy
ovarian enlargement
unexplained vaginal bleeding
ovarian, uterine, or breast cancer
|
|
gptkbp:developer
|
gptkb:Merck_Sharp_&_Dohme
|
|
gptkbp:drugClass
|
gonadotropin
|
|
gptkbp:halfLife
|
~65 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
corifollitropin alfa
|
|
gptkbp:indication
|
women undergoing controlled ovarian stimulation for assisted reproduction
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
follicle-stimulating hormone receptor agonist
|
|
gptkbp:molecularWeight
|
~60 kDa
|
|
gptkbp:pregnancyCategory
|
X (contraindicated)
|
|
gptkbp:product
|
gptkb:protein
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
nausea
abdominal pain
headache
ovarian hyperstimulation syndrome
|
|
gptkbp:target
|
gptkb:FSH_receptor
|
|
gptkbp:UNII
|
6Y7T1FZ1EZ
|
|
gptkbp:usedFor
|
assisted reproductive technology
controlled ovarian stimulation
|
|
gptkbp:bfsParent
|
gptkb:Elonva
|
|
gptkbp:bfsLayer
|
6
|